RECITALS --------Co-Development Agreement • August 1st, 2000 • Nexell Therapeutics Inc • Pharmaceutical preparations • California
CO-DEVELOPMENT AGREEMENT BY AND BETWEEN QLT INC. AND RETINAGENIX, LLC DATED AS OF April 4, 2006Co-Development Agreement • March 1st, 2011 • QLT Inc/Bc • Pharmaceutical preparations • New York
THIS AGREEMENT (this “Agreement”) is entered into effective as of April 4, 2006 (the “Effective Date”), between QLT INC. (“QLT”), a British Columbia corporation, with offices at 887 Great Northern Way, Vancouver, British Columbia, Canada V5T 4T5, and RETINAGENIX, LLC (“RGX”), a Washington limited liability company, with offices at 3530 West Laurelhurst Drive N.E., Seattle, Washington, USA 98105.
CO-DEVELOPMENT AGREEMENTCo-Development Agreement • May 1st, 2014 • SpineZ • Surgical & medical instruments & apparatus • Florida
This Co-Development Agreement (this "Agreement") is made and effective as of the 30th day of September, 2013, by and between SpineZ Corp., a Nevada corporation; and Debride, Inc. a Florida corporation (jointly and severally herein called the "Company"), and James R. Andrews, M.D. (the "Co-Developer").
DATED: OCTOBER 10, 2013 CO-DEVELOPMENT AND REVENUE SHARING AGREEMENT II: Cervical Intraepithelial Neoplasia in HIV/HPV co-infected women (“CIN”) BETWEEN CEL-SCI Corporation AND Ergomed Clinical Research LimitedCo-Development Agreement • April 17th, 2015 • Cel Sci Corp • Biological products, (no disgnostic substances) • New York
CEL-SCI Corporation, a company duly established pursuant to the laws of Colorado, with the registered office at 8229 Boone Boulevard, Suite 802, Vienna, VA, 22182. USA, hereinafter: “CEL-SCI”)
CO-DEVELOPMENT AGREEMENTCo-Development Agreement • April 11th, 2008 • Public Media Works Inc • Services-motion picture & video tape production
This agreement (“Agreement”) is entered into as of 2 April 2008, by and between Fuqua Films, Inc. f/s/o Antoine Fuqua, (“Fuqua Films”) and Public Media Works, Inc. (“PMW”).
CO-DEVELOPMENT AGREEMENTCo-Development Agreement • May 30th, 2017 • American BriVision (Holding) Corp • Pharmaceutical preparations • New York
American BriVision Corporation, a company incorporated under the laws of USA and having it principle place of business at 11 Sawyers Peak Drive, Goshen, NY 10924 USA (“ABVC”)
SECOND AMENDED AND RESTATED CO-DEVELOPMENT AGREEMENT BY AND BETWEEN BAYLOR COLLEGE OF MEDICINE ANDCo-Development Agreement • March 16th, 2022 • Athenex, Inc. • Pharmaceutical preparations • New York
This Second Amended and Restated Co-Development Agreement (the “Second Restated Co-Development Agreement” or “Agreement” herein), effective as of October 12, 2021 (the “Second Restatement Effective Date” or “Effective Date” herein), is by and between (i) Baylor College of Medicine (“Baylor”), a Texas nonprofit corporation having its principal place of business at One Baylor Plaza, Cullen Building, Suite 106A, Houston, Texas 77030, and (ii) Cell Medica Inc., doing business as Kuur Therapeutics, a Texas corporation (“Kuur”). As of the Second Restatement Effective Date, this Second Restated Co-Development Agreement amends and restates that certain Amended and Restated Co-Development Agreement (the “First Restated Co-Development Agreement”), entered into on February 28, 2020 (the “First Restatement Effective Date”) by Baylor and Kuur Therapeutics Ltd. (formerly known as Cell Medica Ltd.), and as assigned by Kuur Therapeutics Ltd. to Cell Medica Inc. on August 26, 2020, which First Restated
AMENDED AND RESTATED CO-DEVELOPMENT AGREEMENT BY AND BETWEEN BAYLOR COLLEGE OF MEDICINE AND KUUR THERAPEUTICS LIMITED (f/k/a CELL MEDICA, LTD.) Original Effective Date: APRIL 29, 2016 Restatement Effective Date: FEBRUARY 28, 2020Co-Development Agreement • August 5th, 2021 • Athenex, Inc. • Pharmaceutical preparations • New York
This Amended and Restated Co-Development Agreement (the “Restated Agreement”), effective as of February 28, 2020 (the “Restatement Effective Date”), is by and between (i) Baylor College of Medicine (“Baylor”), a Texas nonprofit corporation having its principal place of business at One Baylor Plaza, Cullen Building, Suite 106A, Houston, Texas 77030, and (ii) Kuur Therapeutics Limited (formerly known as Cell Medica, Ltd.) (Reg. No. 05620555), a private limited company organized under the laws of England and Wales and having a principal place of business at 1 Canal Side Studios, 8-14 St Pancras Way, London, NW1 0QG, United Kingdom (“Cell Medica” or “Kuur”). As of the Restatement Effective Date, this Restated Agreement amends and restates the Co-Development Baylor Agreement enter into by Baylor and Cell Medica dated April 29, 2016, as such agreement has been amended by that certain First Amendment dated July 12, 2017 and that certain Second Amendment dated February 28, 2019 (collectively,
Certain information has been excluded from this agreement (indicated by “[***]”) because such information (i) is not material and (ii) would be competitively harmful if publicly disclosed.Co-Development Agreement • March 30th, 2020 • PhaseBio Pharmaceuticals Inc • Pharmaceutical preparations • Delaware
This Co-Development Agreement (“Agreement”), made effective as of January 9, 2020 (the “Effective Date”), is by and between PhaseBio Pharmaceuticals Inc., a Delaware corporation, with a principal place of business at 1 Great Valley Parkway, Suite 30, Malvern, Pennsylvania 19355, USA (“PB”), and SFJ Pharmaceuticals X, Ltd. (“SFJ”), an SFJ Pharmaceuticals Group company and corporation organized and existing under the laws of the Cayman Islands, having its principal place of business at SIX, 2nd Floor, Cricket Square PO Box 2681, Grand Cayman, KY1-1111 Cayman Islands (each, a “Party” and collectively, the “Parties”).
CO-DEVELOPMENT AGREEMENT By and between Alnylam Pharmaceuticals, Inc., BXLS V Bodyguard – PCP L.P. AND BXLS Family Investment Partnership V – ESC L.P. Dated August 15, 2020Co-Development Agreement • November 5th, 2020 • Alnylam Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
This Co-Development Agreement (“Agreement”), made effective as of August 15, 2020 (the “Effective Date”), is by and between Alnylam Pharmaceuticals, Inc., a Delaware corporation (“Alnylam”), BXLS V Bodyguard – PCP L.P., a Delaware limited partnership organized and existing under the laws of the state of Delaware (for itself, and as the “Administrative Agent” hereunder), and BXLS Family Investment Partnership V – ESC L.P., a Delaware limited partnership organized and existing under the laws of the state of Delaware (each of BXLS V Bodyguard – PCP L.P. and BXLS Family Investment Partnership V – ESC L.P., a “Blackstone Entity” and collectively, “Blackstone”) (each, a “Party” and collectively, the “Parties”).
CO-DEVELOPMENT AGREEMENT THIS AGREEMENT (the "Agreement") is entered into and effective this 20 day of May 1998, the same date affixed hereto by the party last signing this Agreement, by and between Biomed (UK) Ltd ("Biomed") of St Budeaux, Packhorse...Co-Development Agreement • October 13th, 1999 • Bioenvision Inc • Non-operating establishments • England
FIRST AMENDMENT TO CO-DEVELOPMENT AGREEMENTCo-Development Agreement • April 17th, 2015 • Cel Sci Corp • Biological products, (no disgnostic substances)
This First Amendment (“First Amendment”) to the Co-Development Agreement II and Revenue Sharing Agreement (“Co-Development Agreement II”) made on October 24, 2013, between CEL-SCI Corporation, a company duly established pursuant to the laws of Colorado, with the registered office at 8229 Boone Boulevard, Suite 802, Vienna, VA, 22182, USA (hereinafter: “CEL-SCI”) and Ergomed Clinical Research, Ltd., a company duly established pursuant to the laws of England, with registered offices at The Surrey Technological Centre, 40 Occam Road, Guildford, Surrey, GU2 7YG, England (hereinafter: “Ergomed”) is effective as of October 24, 2013.
SECOND AMENDMENT TO CO-DEVELOPMENT AGREEMENTCo-Development Agreement • May 25th, 2007 • Bioenvision Inc • Pharmaceutical preparations
This Second Amendment to Co-Development Agreement (this “Second Amendment”) is made as of May 24, 2007, by and between Southern Research Institute (“SRI”) and Bioenvision, Inc. (as successor-in-interest to Eurobiotech Group, Inc.) (“Bioenvision”).
CO-DEVELOPMENT AGREEMENT THIS AGREEMENT (the "Agreement") is entered into and effective this 19 day of May 1998, the same date affixed hereto by the party last signing this Agreement, by and between Bioheal Ltd ("Bioheal") of International House,...Co-Development Agreement • October 13th, 1999 • Bioenvision Inc • Non-operating establishments • England
Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. AMENDMENT NO. 1 TO CO-DEVELOPMENT AGREEMENTCo-Development Agreement • February 10th, 2022 • Alnylam Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
This AMENDMENT NO. 1 TO CO-DEVELOPMENT AGREEMENT (this “Amendment”) is entered into as of November 23, 2021 (the “Effective Date”), by and between Alnylam Pharmaceuticals, Inc., a Delaware corporation (“Alnylam”), BXLS V Bodyguard – PCP L.P., a Delaware limited partnership organized and existing under the laws of the state of Delaware, and BXLS Family Investment Partnership V – ESC L.P., a Delaware limited partnership organized and existing under the laws of the state of Delaware (collectively, “Blackstone”) (each, a “Party” and collectively, the “Parties”).
ContractCo-Development Agreement • March 21st, 2024 • NextCure, Inc. • Pharmaceutical preparations • New York
CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. OMITTED INFORMATION HAS BEEN REPLACED WITH ASTERISKS [***]
EXHIBIT 10.1 CO-DEVELOPMENT AGREEMENT This Agreement, effective on March 25, 2003, is by and between DMI BioSciences, Inc., having a place of business at 3601 South Clarkson Street, Suite 420, Englewood, Colorado 80110, and its Affiliates...Co-Development Agreement • September 16th, 2003 • Enhance Biotech Inc • Services-personal services • New York
CO-DEVELOPMENT AGREEMENTCo-Development Agreement • April 16th, 2024 • Qualigen Therapeutics, Inc. • Pharmaceutical preparations • Florida
THIS CO-DEVELOPMENT AGREEMENT (this “Agreement”) is entered into as of April 11, 2024, and effective as of the date the Initial Payment (defined below) is made (the “Effective Date”), by and between Marizyme, Inc., a Nevada corporation (the “Company”) and Qualigen Therapeutics, Inc., a Delaware corporation (“Qualigen”). The Company and Qualigen are sometimes referred to herein each as a “Party” and collectively as the “Parties”.
ContractCo-Development Agreement • August 10th, 2022 • Cullinan Oncology, Inc. • Biological products, (no disgnostic substances) • New York
Certain confidential information contained in this document, marked by [*****], has been omitted because it is not material and would likely cause competitive harm to Cullinan Oncology, Inc. if publicly disclosed.
